deletions | additions       diff --git a/subsection_Hypometabolism_on_FDG_PET__.tex b/subsection_Hypometabolism_on_FDG_PET__.tex  index f44c4ab..ae1c60b 100644  --- a/subsection_Hypometabolism_on_FDG_PET__.tex  +++ b/subsection_Hypometabolism_on_FDG_PET__.tex 
...
\subsection{Hypometabolism on FDG-PET} \subsection{Neurodegeneration}  Two main imaging biomarkers targeting neurodegeneration are FDG-PET scan and structural MRI.  Cerebral metabolic rate of glucose can be measured by PET scan using the tracer fluorine-18 (F-18) fluorodeoxyglucose (FDG).  In AD, the reductions in cerebral metabolism is well established and is one of the two biomarkers targeting neurodegeneration.  The glucose metabolism measures with FDG-PET scan have been used with good accuracy to distinguish AD from both NCs and other dementias\cite{Mosconi_2007,Ballard_2011}.  FDG-PET has also been used to predict MCI to AD converters with better accuracy than structural MRI \cite{Yuan_2008}. Longitudinal structural MRIs have been widely used as an imaging biomarker for AD.